Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
about
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Safety and efficacy of second- ...... results of a phase 1/2 study.
@en
Safety and efficacy of second- ...... results of a phase 1/2 study.
@nl
type
label
Safety and efficacy of second- ...... results of a phase 1/2 study.
@en
Safety and efficacy of second- ...... results of a phase 1/2 study.
@nl
prefLabel
Safety and efficacy of second- ...... results of a phase 1/2 study.
@en
Safety and efficacy of second- ...... results of a phase 1/2 study.
@nl
P2093
P2860
P50
P1433
P1476
Safety and efficacy of second- ...... results of a phase 1/2 study.
@en
P2093
Dong-Wook Kim
H Jean Khoury
Jeff H Lipton
Kay Noonan
Liza DeAnnuntis
Mark Shapiro
Nathalie Bardy-Bouxin
Philippe Schafhausen
Rocco Crescenzo
P2860
P356
10.3324/HAEMATOL.2017.171249
P577
2018-05-17T00:00:00Z